Kabra Drugs Turns Profitable in FY26 with ₹4.96 Crore Net Profit

HEALTHCAREBIOTECH
Whalesbook Corporate News Logo
AuthorKavya Nair|Published at:
Kabra Drugs Turns Profitable in FY26 with ₹4.96 Crore Net Profit
Overview

Kabra Drugs Limited reported a significant turnaround in FY26, posting a net profit of ₹4.96 crore after a loss in FY25. The company also adopted a new tax regime.

Instant Stock Alerts on WhatsApp

Used by 10,000+ active investors

1

Add Stocks

Select the stocks you want to track in real time.

2

Get Alerts on WhatsApp

Receive instant updates directly to WhatsApp.

  • ✓Quarterly Results
  • ✓Concall Announcements
  • ✓New Orders & Big Deals
  • ✓Capex Announcements
  • ✓Bulk Deals
  • ✦And much more
Add StocksGet it on Google PlayDownload on the App Store

Kabra Drugs Achieves Profitability in FY26

Kabra Drugs Limited reported a net profit of ₹4.96 crore for the financial year ended March 31, 2026. This marks a significant turnaround from a net loss of ₹1.09 crore in the previous financial year. Revenue from operations stood at ₹92.74 crore.

Reader Takeaway: Profitability achieved with unmodified audit; accounting adjustments noted.

What just happened

Kabra Drugs Limited announced its audited financial results for the financial year ended March 31, 2026. The company reported a net profit after tax of ₹4.96 crore, a positive shift from a net loss of ₹1.09 crore in the prior year.

Why this matters

This turnaround to profitability is a key development for shareholders, indicating improved financial performance. An unmodified audit opinion signifies that the financial statements present a true and fair view.

The backstory

In the financial year 2025, Kabra Drugs had reported a net loss of ₹1.09 crore. The company also underwent a transition to the concessional tax regime under Section 115BAA of the Income-tax Act, 1961.

What changes now

The company's financial trajectory has shifted positively. Investors will be looking for sustained profitability in the upcoming financial periods.

Risks to watch

Management identified and corrected an oversight regarding the impact of Ind AS 116 (Leases) in the final audit. While the overall audit opinion was unmodified, this points to a need for enhanced accuracy in interim reporting.

Peer comparison

Kabra Drugs' return to profitability in FY26 contrasts with its FY25 loss. Specific peer comparisons are not provided in the filing.

Context metrics (time-bound)

  • Revenue from Operations (FY26): ₹92.74 crore
  • Net Profit after Tax (FY26): ₹4.96 crore
  • Net Loss after Tax (FY25): ₹1.09 crore
  • Total Assets (as at 31/Mar/26): ₹86.27 crore
  • Total Equity (as at 31/Mar/26): ₹29.61 crore

What to track next

Investors should monitor the sustainability of this profit in the upcoming quarters and observe any further impact of the adopted tax regime.

Get stock alerts instantly on WhatsApp

Quarterly results, bulk deals, concall updates and major announcements delivered in real time.

Add Stocks
Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.